Neuland Lab Results Analysis

Operating Revenue for Q2FY26 is Rs. 514 Crs., 65.45% growth YoY, Total Income is Rs. 516 Crs., 63.74% growth YoY, EBITDA is Rs. 156 Crs., 150% growth YoY, EBITDA Margin is 30.24% improved by 1023 Basis points YoY, PBT Rs. 129 Crs., 162% growth YoY, PAT Rs. 97 Crs. 195% growth YoY. On QoQ basis Op. Revenue is up by 75.7%, Total Income is up by 71.7%, EBITDA is also up by 351%, EBITDA Margin increased by 1847 basis points, PBT is up by 637% and PAT is also up by 597%. Q2 FY26 delivered all-time high revenue with sharp margin expansion, driven by commercial CMS shipments of the top two molecules and now expecting Commercialization of another molecule this year.